Ipilimumab, Pluvicto 1 000 MBq/mL solution for injection/infusion, Ipilimumab clinical trials

A phase I study of neoadjuvant treatment with 177-Lutetium-PSMA-617 with Ipilimumab in subjects with very high-risk prostate cancer who are candidates for radical prostatectomy (NEPI Trial)

This study looks at a new combination of treatments, Ipilimumab and Pluvicto, for men with very high-risk prostate cancer before they have surgery. Researchers want to see if this combination is safe and helps shrink the cancer, making surgery easier and more effective.